GUERBET news, videos and press releases
For more news please use our advanced search feature.
GUERBET - More news...
GUERBET - More news...
- GUERBET : H1 2024 results.
- GUERBET : H1 2024 revenue.
- Guerbet : NUCLIDIUM and Guerbet Form Strategic Partnership to Support the Advancement of targeted Copper-based Radiotheranostics.
- Guerbet: Change in Guerbet’s Board of Directors.
- Guerbet: 2023 full-year results.
- Guerbet strengthens its Executive Committee with two new appointments to consolidate its medium and long-term ambitions.
- Guerbet: 2023 revenue
- Guerbet: Death of Michel Guerbet, son of the founder and company director for over 30 years.
- Guerbet: CHMP positive opinion
- Guerbet: 2023 half-year results
- Guerbet: Guerbet wins PI-CAI Grand Challenge on detection of prostate cancer
- Guerbet: Guerbet strengthens its Executive Committee with two new appointments to accelerate its commercial and industrial development
- Guerbet: 2022 annual results
- Guerbet: 2022 revenue
- Guerbet: 2023 Strategic Priorities
- Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
- Guerbet: Intrasense opens its share capital to the Guerbet Group, which announces its intent to file a voluntary tender offer under the same price conditions
- Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting
- Guerbet: Guerbet announces a change in governance for its Artificial Intelligence projects
- Guerbet: Revenue at September 30, 2022
- Guerbet obtains one million euros of public funding from Bpifrance (France 2030 investment plan) for a project developing artificial intelligence for the early detection of pancreatic cancer
- Guerbet announces U.S. Food and Drug Administration (FDA) approval of Elucirem™ (Gadopiclenol)
- Guerbet: Q1 2022 revenue
- Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA
- Guerbet - Gadopiclenol Marketing Authorization dossier submissions accepted for review by EMA and FDA - Priority Review granted by US-FDA March 28, 2022
- Guerbet: 2021 annual results
- Guerbet expands portfolio with microcatheters and guidewires for interventional imaging and embolization
- Guerbet Announces Appointment of Jared Houk as Commercial Vice President for North America
- Guerbet: 2021 Corporate Social Responsibility Gaïa-Index: Guerbet consolidates its position as leader in the “Healthcare” category
- Guerbet and Bracco Imaging Announce a Global Strategic Collaboration Agreement for Gadopiclenol
